News

Article

NeurologyLive® Friday 5 — October 18, 2024

Key Takeaways

  • New myasthenia gravis treatments show promise in reducing corticosteroid use, offering potential therapeutic benefits.
  • Cladribine capsules are being tested in a phase 3 study for efficacy and safety in generalized myasthenia gravis.
SHOW MORE

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 18, 2024.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Therapeutic Benefits of Steroid-Sparing Effect From New Myasthenia Gravis Medications: Christopher Scheiner, MD, PhD

The neuromuscular specialist at the University of Tennessee Medical Center provided clinical insight on a retrospective analysis studying the long-term corticosteroid patterns of approved treatments for generalized myasthenia gravis. [WATCH TIME: 5 minutes]

Therapeutic Benefits of Steroid-Sparing Effect From New Myasthenia Gravis Medications: Christopher Scheiner, MD, PhD

2: Innovative MyClad Study Testing Cladribine Capsules in Generalized Myasthenia Gravis: Henry Kaminski, MD

The Meta A. Neumann Professor of Neurology at George Washington University provided an overview of a new phase 3 study testing the efficacy and safety of cladribine versus placebo in generalized myasthenia gravis. [WATCH TIME: 3 minutes]

Innovative MyClad Study Testing Cladribine Capsules in Generalized Myasthenia Gravis: Henry Kaminski, MD

3: Understanding the Therapeutic Potential of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS

The director of the myasthenia gravis clinic at Yale University provided clinical insight on promising phase 3 data assessing inebilizumab, an FDA-approved therapy for NMOSD, in patients with myasthenia gravis. [WATCH TIME: 4 minutes]

Understanding the Therapeutic Potential of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS

4: NeuroVoices: John Winkelman, MD, PhD, on Taking a Major Shift Away From Dopamine Agonists in the Revised Guidelines for Restless Leg Syndrome Treatment

In our latest Q&A for NeuroVoices, the chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital discussed the newly updated treatment guidelines for the treatment of restless leg syndrome.

NeuroVoices: John Winkelman, MD, PhD, on Taking a Major Shift Away From Dopamine Agonists in the Revised Guidelines for Restless Leg Syndrome Treatment

5: Roundtable Discussion: Unmasking Long COVID Through Understanding Prevalence and Diagnosis

In episode 1 of our latest Roundtable Discussion video series, titled "A Deep Dive: Understanding the Neurological Toll of Long COVID," experts discussed Long COVID prevalence, underreporting, accurate diagnosis, and emphasized that Long COVID serves as an umbrella term.

Unmasking Long COVID Through Understanding Prevalence and Diagnosis
Related Videos
2 experts in this video
Michael Levy, MD, PhD, is featured in this series.
2 experts in this video
Alexander C. Whiting, MD
2 experts in this video
2 experts in this video
© 2024 MJH Life Sciences

All rights reserved.